Skip to main content


  • Case report
  • Open Access

Report of methamphetamine use and cardiomyopathy in three patients

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3 and
  • 4, 5Email author
DARU Journal of Pharmaceutical Sciences201220:20

  • Received: 4 May 2012
  • Accepted: 17 May 2012
  • Published:



Methamphetamine (meth) is a stimulant used illegally around the world, including in Iran. Cardiomyopathy and cardiac failure may occur following chronic meth use and may cause the patients referred to the emergency department.

Case reports

A 28-year old man and two women, ages 29 and 31-year-old, with a history of meth use, were admitted to the emergency department with severe dyspnea at rest. Each had sinus tachycardia with tachypnea and an echocardiogram that showed severe systolic dysfunction consistent with heart failure. Additional evaluation in the hospital revealed cardiomyopathy with no other etiology other than the meth use.


There are several reports that show an increase in frequency of meth use, suggesting that cardiomyopathy and acute heart failure may be a new medical concern.


  • Cardiomyopathy
  • Congestive heart failure
  • Methamphetamine


Substance misuse is a major health problem in all parts of the world. Methamphetamine (meth) is a synthetic amine stimulant that is a highly addictive stimulant, and is currently the most widespread illegal amine drug used in the United States [1]. Its use has increased during the past two decades, especially in teenagers [2, 3]. The last report by the Iranian drug control headquarters showed that only 3.6% of substance users in Iran used meth [4]. However, in recent years the local production of meth has risen and its price has decreased, resulting in growing use of the drug. Nonofficial reports estimate that meth is currently the second or third most widely used illicit substance in Iran [5].

Chronic use results in a number of medical complications and fatalities [6]. Meth directly affects multiple organs, as well as causes hypertension and tachycardia, cardiovascular complications such as myocardial infarction, dysrhythmias, ventricular hypertrophy, pulmonary edema and hypertension, cerebral stroke and hemorrhage, seizures, psychosis, and occasionally death may occur [7]. Due to the combination of some of these effects, long term users may develop cardiomyopathy. Although the incidence of methamphetamine cardiomyopathy is unknown, we report three cases of methamphetamine cardiomyopathy in Iran.

Case reports

Three patients, a 28-year-old man, and a 29 and 31-year-old woman, were admitted separately in Loghman Hakim Hospital, a referral and tertiary care medical center in Tehran, Iran. All had a chief complain of severe dyspnea at rest. The 28-year-old man also complained of exertional chest pain which was typical ischemic chest pain. On arrival, all of them were conscious and followed commands. None of them had any underlying disease and the only pertinent positive in their medical history was meth use, which was supported by a urinary drug screen. The duration of meth use in the man was one year and was 2 and 3 years in the 29 and 31-year-old woman, respectively.

Vital signs on arrival included: BP: 90/70 mmHg, 100/60 mmHg and 90/60 mmHg, PR: 120, 104 and 110 beats/min and RR: 26, 32 and 22 breaths/min, respectively. A chest radiograph showed pulmonary congestion and an electrocardiogram (ECG) revealed sinus tachycardia, poor R wave progression in the pericardial leads, and T wave inversions in precordial leads in all three patients. Also, the second patient showed right axis deviation (135°) and the third patient had QS wave in the inferior leads. Measurement of cardiac troponin, evaluation of renal and thyroid function tests, measurement of serum electrolytes, blood lipids and a complete blood cell count (CBC) are shown in Table 1. A normal fasting transferrin saturation test was subsequently performed, ruled out hemochromatosis as an etiology of the cardiomyopathy.
Table 1

Laboratory data of the patients at admission in the hospital and during hospitalization

31-year-old woman

29-year-old woman

28-year-old man

Laboratory parameter (Normal range)

101 (1)

48 (1)

66 (1)

Urea (15–45 mg/dL)

1.5 (1)

1.0 (1)

1.5 (1)

Creatinine (0.7–1.4 mg/dL)

136 (1)

137 (1)

145 (1)

Na (135–150 mEq/L)

4.8 (1)

4.9 (1)

4.9 (1)

K (3.2–5.5 mEq/L)

8.5 (3)

9.0 (3)

9.9 (3)

Calcium (8.5–10.5 mg/dL)

5.1 (3)

4.6 (3)

4.4 (3)

Phosphorus (2.5–4.8 mg/dL)

2.1 (3)

2.0 (3)

1.9 (3)

Magnesium (1.9–2.5 mg/dL)

73 (1)

68 (1)

102 (1)

Creatinine phosphokinase (24–195 U/L)

15 (1)

8 (1)

16 (1)

CPK-MB (0–24 U/L)

14.1 (1)

14.7 (1)

12.6 (1)

Prothrombin time (12–14 second)

26.0 (1)

28.0 (1)

34.5 (1)

Partial thromboplastin time (24–36 second)

1.63 (1)

1.8 (1)

1.27 (1)

International normalized ratio (up to 1)

10700 (1)

17900 (1)

14100 (1)

White blood cell (4000–10000/μL)

11.9 (1)

8.1 (1)

12.4 (1)

Hemoglobin (12–14 g/dL)

34.3 (1)

28.5 (1)

39.9 (1)

Hematocrit (30–45%)

333000 (1)

215000 (1)

246000 (1)

Platelet (150000-350000/μL)

13 (3)

9 (3)

3 (2)

Erythrocyte sedimentation rate (0–10 mm/h)




Thyroid function tests




Human immune deficiency virus

106 (3)

104 (3)

248 (3)

Total cholesterol levels (mg/dL)

95 (3)

110 (3)

245 (3)

Serum triglycerides (mg/dL)

35 (3)

31 (3)

161 (3)

LDL cholesterol (mg/dL)

52 (3)

51 (3)

38 (3)

HDL cholesterol (mg/dL)

72 (1)

90 (1)

70 (2)

Fasting blood sugar (60–110 mg/dL)

0.4 (3)


0.5 (3)

Troponin (adult < 1.3 mg/mL)

ND = Not determined.

The data in the parenthesis show the days after admission.

The 28-year-old man underwent coronary angiography due to concomitant chest pain, which was normal. All three patients underwent two-dimensional echocardiography with Doppler during the initial evaluation, and revealed severe decrease in left ventricular ejection fraction (LVEF) in each.

The patients were treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-adrenergic antagonists, diuretics and digoxin and were discharged after 7, 10 and 20 days hospitalization. At the time of discharge, the 2 women were classified as having New York Heart Association class I (NYHA-I) and the man NYHA-III heart failure [8]. Outpatient visits were scheduled and the patients have been followed up for 9, 5 and 6 months respectively; no clinical or echocardiographic improvements were noted. The man patient was considered for heart transplantation due to his severe symptoms at rest despite optimal medical treatment.

Written informed consent was obtained from the patients for publication of this report and any accompanying images.


Meth is relatively easy to manufacture making its production inexpensive and widely available. Its low cost and long duration of action have made it a very desirable drug for use [5]. In addition, its high addictive potential and stimulant effects have made its use a serious health problem [9, 10].

Meth affects multiple organs, including the cardiovascular system [7]. One report suggests that 40% of young patients with cardiomyopathy are meth abusers [11]. In another study, meth use was present in at least 5% of all patients presenting to the emergency department with heart failure [12]. Previous case reports and case series suggest that meth exposure is potentially associated with structural and functional changes of myocytes, as well as clinical manifestations of cardiomyopathy and congestive heart failure [13]. In Iran, the frequency of meth use especially within the young population has increased in the recent years [14, 15], raising concerns for the future development of cardiomyopathy and acute decompensate heart failure in this group.

Diagnosing the etiology of dyspnea can be difficult, in part because several disorders may coexist. However, our patients were young and had no underlying medical problems except for meth use. The clinical evaluation found only left ventricular systolic dysfunction in all three patients. Although endomyocardial biopsies were not performed, the failure of clinical or echocardiographic improvement over time supports the diagnosis of meth-associated cardiomyopathy.

The most probably mechanisms for meth cardiotoxicity relates to the potent central and peripheral sympathomimetic effects of meth [16]. The increase in circulating catecholamine levels caused by this drug causes coronary vasospasm, persistent tachycardia and hypertension, and/or direct myocardial toxicity [1719].

As in our cases, patients with meth-associated cardiomyopathy have a significantly lower LVEF or more severe ventricular dilation when compared with patients with cardiomyopathy from other causes [11, 20]. As there is no antidote for the treatment of cardiac toxicity of meth use in various countries [21, 22], some cardiac effects of its use, like myocyte hypertrophy and fibrosis are relatively irreversible [23], and cardiac toxicity may result in sudden and unexpected death [24]. By the way, recovery of left ventricular dysfunction in patients with meth-induced cardiomyopathy has been described [25], although recovery of cardiac function did not occur in any of our cases during follow up.

Recognition of cardiomyopathy and acute heart failure as a complication associated with the meth use may be a new medical concern.


Authors’ Affiliations

Internal Medicine Department, Loghman Hakim Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
New York University School of Medicine, New York City Poison Control Center, Bellevue Hospital, New York, USA
Faculty of Pharmacy, Pharmaceutical Research Center, Tehran University of Medical Sciences, Tehran, Iran
Clinical Toxicology Department, Loghman Hakim Hospital Poison Center, Faculty of Medicine, and Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Clinical Toxicology Department, Loghman Hakim Hospital Poison Center, Kamali Street, South Karegar Avenue, Tehran, 1333431151, Iran


  1. NIDA Research Report Series: Methamphetamine abuse and addiction. NIH Publication Number 02–4210, Printed. 1998,, April , Reprinted January 2002,Google Scholar
  2. Gonzales R, Mooney L, Rawson RA: The methamphetamine problem in the United States. Annu Rev Public Health. 2010, 31: 385-398. 10.1146/annurev.publhealth.012809.103600.PubMed CentralView ArticlePubMedGoogle Scholar
  3. McKetin R, Kozel N, Douglas J, Ali R, Vickasingam B, Lund J, Li JH: The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev. 2008, 27: 220-228. 10.1080/09595230801923710.View ArticlePubMedGoogle Scholar
  4. Drug Control in 2008: Annual report and rapid situation assessment. Islamic Republic of Iran, Drug Control Headquarters (Tehran, 2009).,
  5. United Nations Office on Drugs and Crimes: In World Drug Report 2009. 2009, United Nations Office on Drugs and Crimes: Vienna, Retrieved from Scholar
  6. Yu Q, Larson DF, Watson RR: Heart disease, methamphetamine and AIDS. Life Sciences. 2003, 73: 129-140. 10.1016/S0024-3205(03)00260-1.View ArticlePubMedGoogle Scholar
  7. Chiang WK: Amphetamines. Goldfrank's Toxicologic emergencies. Edited by: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS. 2006, New York: McGraw-Hill Co, 1118-1132. 8Google Scholar
  8. The Stages of Heart Failure – NYHA Classification. available at 07/09/2011
  9. Krasnova IN, Cadet JL: Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009, 60: 379-407. 10.1016/j.brainresrev.2009.03.002.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Desai RI, Paronis CA, Martin J, Desai R, Bergman J: Monoaminergic psychomotor stimulants: discriminative stimulus effects and dopamine efflux. J Pharmacol Exp Ther. 2010, 333: 834-843. 10.1124/jpet.110.165746.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Yeo KK, Wijetunga M, Ito H, Efird JT, Tay K, Seto TB, Alimineti K, Kimata C, Schatz IJ: The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007, 120: 165-171. 10.1016/j.amjmed.2006.01.024.View ArticlePubMedGoogle Scholar
  12. Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF: Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol. 2008, 102: 1216-1219. 10.1016/j.amjcard.2008.06.045.View ArticlePubMedGoogle Scholar
  13. Wijetunga M, Seto T, Lindsay J, Schatz I: Crystal methamphetamine associated cardiomyopathy: tip of the iceberg?. J Toxicol Clin Toxicol. 2003, 41: 981-986. 10.1081/CLT-120026521.View ArticlePubMedGoogle Scholar
  14. Amiri ZM, Shakib AJ, Moosavi AK: Prevalence and risk factors of ecstasy use among college students in Astara, Islamic Republic of Iran. East Mediterr Health J. 2009, 15: 1192-1200.PubMedGoogle Scholar
  15. Momtazi S, Rawson R: Substance abuse among Iranian high school students. Curr Opin Psychiatry. 2010, 23: 221-226. 10.1097/YCO.0b013e328338630d.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Darke S, Kaye S, McKetin R, Duflou J: Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008, 27: 253-262. 10.1080/09595230801923702.View ArticlePubMedGoogle Scholar
  17. Turdi S, Schamber RM, Roe ND, Chew HJ, Culver B, Ren J: Acute methamphetamine exposure inhibits cardiac contractile function. Toxicol Lett. 2009, 189: 152-1528. 10.1016/j.toxlet.2009.05.015.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, Alexoff D: Distribution and pharmacokinetics of methamphetamine in the human body: Clinical implications. PLoS One. 2010, 5 (12): e15269-10.1371/journal.pone.0015269.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Kaye S, McKetin R, Duflou J, Darke S: Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007, 102: 1204-1211. 10.1111/j.1360-0443.2007.01874.x.View ArticlePubMedGoogle Scholar
  20. Ito H, Yeo KK, Wijetunga M, Seto TB, Tay K, Schatz IJ: A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol. 2009, 32: E18-E22.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Nikfar S, Khatibi M, Abdollahi-Asl A, Abdollahi M: Cost and utilization study of antidotes: an Iranian experience. Int J Pharmacol. 2011, 7: 46-49.View ArticleGoogle Scholar
  22. Shadnia S, Garlich FM: A comparison between the use and availability of antidotes in Iran and United States of America. Int J Pharmacol. 2011, 7: 799-800.View ArticleGoogle Scholar
  23. Islam MN, Kuroki H, Hongcheng B, Ogura Y, Kawaguchi N, Onishi S, Wakasugi C: Cardiac lesions and their reversibility after long term administration of methamphetamine. Forensic Sci Int. 1995, 75: 29-43. 10.1016/0379-0738(95)01765-B.View ArticlePubMedGoogle Scholar
  24. Jacobs W: Fatal amphetamine-associated cardiotoxicity and its medicolegal implications. Am Journal Forensic Med Pathol. 2006, 27: 156-160. 10.1097/01.paf.0000188082.68009.10.View ArticleGoogle Scholar
  25. Srikanth S, Barua R, Ambrose J: Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology. 2008, 109: 188-192. 10.1159/000106681.View ArticlePubMedGoogle Scholar


© Sadeghi et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.